MAIA (MAIA Biotechnology Inc) Long-Term Debt

Corporate emblem and logo of MAIA Bio (MAIA)

MAIA Biotechnology (MAIA) developments in immuno-oncology are completely decoupled from economic cycles or seasonal fluctuations. Business profitability relies on creating cutting-edge anti-tumor agents by targeting telomeres. This chart of current quotes on GURU.Markets reflects the price action of a company whose financial stability stands at 0.00 due to the systematic use of reserves to fund costly clinical trials.

MAIA (MAIA Biotechnology Inc) Company Long-Term Debt history from 04/28/2023 to 10/28/2026

Financial and market metric breakdowns for MAIA Biotechnology Inc (MAIA)

- price and consensus price forecast:
Stock Quotes MAIABiotech.com|MAIA - Price Target Chart
- market capitalization data:
Market Value MAIA Biotechnology|MAIA - Total Company Value
- book capitalization data:
Net Assets per Single Share MAIA Biotechnology|MAIA - Company Book Value|Market-to-Book Ratio MAIABiotech.com|MAIA - Company Total Assets
- debt and liquidity data:
Debt to Capital Ratio MAIA Biotechnology|MAIA - Long-Term Debt to Equity Ratio|Current Liabilities to Capital MAIA Bio|MAIA - Company Total Debt|Debt to Net Assets Ratio MAIA Biotechnology|MAIA - Company Long-Term Debts|Short-Term Debt Volume MAIA Biotechnology
Comprehensive company analysis:MAIA (MAIABiotech.com)
Mass-produced product of MAIA Biotechnology, Inc.

Developing unique telomerase inhibitors requires significant capital expenditures, making the monitoring of MAIA Biotechnology (MAIA) long-term liabilities critical for assessing financial stability. This indicator aggregates all borrowed funds with a maturity of more than one year, allowing this long-term liability chart to track deleveraging rates and the balance between reducing debt load and preserving resources for expansion.

Competing companies

immunitybio.com - Company Long-Term Liabilities|IMCR (Immunocore) - Company Long-Term Debt|JANX: Long-Term Debt|Arcus Bio (RCUS) - Company Long-Term Debt|ZYME (Zymeworks Biopharmaceuticals) - Company Long-Term Debt|Company Long-Term Debt TNGX (Tango Therapeutics)|Long-Term Debt iovance.com|IMTX: Company Long-Term Debts|Long-Term Indebtedness Xencor Inc XNCR|CMPX: Company Long-Term Liabilities|REPL - Long-Term Debt|Company Long-Term Liabilities Lyell Immunopharma (LYEL)|IPHA - Company Long-Term Loans and Borrowings|pyxisoncology.com - Company Long-Term Debts|CGEN (Compugen) - Long-Term Debt Volume|Company Long-Term Debt IOBT|Company Long-Term Liabilities STRO|Company Long-Term Debt INKT (MiNK Therapeutics, Inc.)|Company Long-Term Liabilities werewolftx.com HOWL|Company Long-Term Liabilities IMMX (Immix Biopharma)|alxoncology.com - Company Long-Term Debts|Cue Biopharma (CUE) - Company Long-Term Debt|PDSB: Company Long-Term Indebtedness|Company Long-Term Debt SONN|Long-Term Debt liminatuspharma.com|LAVA Therapeutics NV - Company Long-Term Liabilities|Long-Term Indebtedness NextCure Inc (NXTC)|Company Long-Term Liabilities Leap Therapeutics, Inc.|Amount of Long-Term Liabilities intensitytherapeutics.com (INTS)|Company Long-Term Debts Sensei Biotherapeutics, Inc.|Company Long-Term Loans and Borrowings therivabio.com TOVX|GRTS (Gritstone Bio) - Company Long-Term Debts|KA: Long-Term Debt|Company Long-Term Debt NexImmune Corp NEXI|Turnstone Biologics Corp. (TSBX) - Company Long-Term Loans and Borrowings|VCNX (Vaccinex, Inc.) - Company Long-Term Debts|Company Long-Term Debts HARP